Thank you for your interest and your time!

1 Now you on IRTU.online

2 Briefly

1. Follow us on X.com (ex. Twitter)

2. Use “Translate” button in your browser if you want this page in your native language

3. Look at “Conference time” section

4. Look at “Conference program” section

5. Look at “How I can get to the conference?” section

3 Conference time

Important

Important: All presentations use Conference time (Moscow time zone MSK (Moscow Standard Time) UTC/GMT +3 hours.). If you need to calculate time in your country please use this link

Please look at the left – you can see Conference time

3.1 Example of Time zones conversion

Conference time	Local time	City, Country
10:00	10:30	Tehran, Iran
10:00	10:00	Moscow, Russia
10:00	10:00	Ankara, Türkiye
10:00	12:00	Tashkent, Uzbekistan

4 Conference program

You can download program in pdf or please select below

Choose the day OR Click here to hide

April 26, 2025 - Day 1

Satellite symposiums of companies, satellite reports of companies

Hall 1

	Chairmen Dr. Elena Parovichnikova, MD, Moscow, Russia Dr. Sergey Bondarenko, MD, St. Petersburg, Russia
	10.00-10.15		Targeted therapy for refractory and relapsed AML-basic option to achieve remission before performing HSCT Dr. Irina Lukyanova, MD, Moscow, Russia with the support of the Astellas
	10.15-10.20		Questions
	10.20-10.35		The advantages of TKI maintenance therapy llafter ao-HSCT Dr. Sergey Bondarenko, MD, St. Petersburg, Russia with the support of the Astellas
	10.35-10.40		Questions
	10.40-11.00		Treatment of newly diagnosed acute myeloid leukemia: can we do better? Dr. Larisa Girshova, MD, St. Petersburg, Russia with the support of Pfizer
	11.00-11.05		Questions
	11.05-11.20		CAR-T therapy: evolving art of ALL treatment Dr. Olga Aleshina, MD, Moscow, Russia with the support of Novartis
	11.20-11.25		Questions
	11.25-11.35		Discussion

Hall 2

	Chairmen Dr. Evgeny Zvonkov, MD, Moscow, Russia Prof. Dr. Evgeny Nikitin, MD Moscow, Russia
	10.00-10.20		Mosunetuzumab: how to improve treatment results of relapsed follicular lymphoma? Dr. Ekaterina Gitelzon MD, Moscow, Russia with the support of the JSC «Roche-Moscow»
	10.20-10.25		Questions
	10.25-10.45		Glofitamab in the treatment of relapsed/refractory DLBCL: from theory to practice Dr. Evgeny Zvonkov, MD, Moscow, Russia with the support of the JSC «Roche-Moscow»
			Questions
	10.45-10.50		Nanolek Satellite Symposium Moderator Prof. Dr. Evgeny Nikitin, MD, Moscow, Russia
	10.50-11.10		Current CLL 1st line treatment options, depending on risk factors Dr. Inga Piskunova, MD,  Moscow, Russia with the support of the Nanolek
	11.10-11.15		Questions
	11.15-11.35		Analysis of treatment tactics in R/R CLL Dr. Maria Kislova, MD, Moscow, Russia with the support of the Nanolek
	11.35-11.40		Questions
	11.40-11.55		Real world evidence in CLL treatment: last decade and future overview Prof. Dr.Evgeny Nikitin, MD, Moscow, Russia with the support of LLS «Johnson&Johnson»
	11.55 -12.00		Questions

Hall 1

	Chairmen Dr.Anahit Melikyan, MD, Moscow Russia Prof. Dr. Anna Turkina, MD, Moscow, Russia Dr. Nadezhda Zozulya, MD, Moscow, Russia
	12.00-12.15		Results of asciminib treatment in CML patients with the T315I mutation in the MAP program Dr. Anna Petrova, MD, Moscow, Russia with the support of the Novartis
	12.15-12.20		Questions
	12.20 -13.00		Chronic GVHD: modern approaches to treatment in the Russian Federation Dr. Mikhail Drokov, MD, Moscow, Russia Prof. Dr. Ivan Moiseev, MD, St. Petersburg, Russia with the support of the JSC «Sanofi Russia»
	13.00-13.15		Experience in the diagnosis and treatment of systemic mastocytosis at the NMRC for Hematology the Ministry of Health of the Russian Federation Dr. Anahit Melikyan, MD, Moscow, Russia with the support of the Novartis
	13.15-13.20		Questions
	13.20-13.40		General surgery in the era of emicizumab: Russian experience and key conclusions Dr. Sergey Shutov, MD, Moscow, Russia with the support of the JSC «Roche-Moscow»
	13.40-13.45		Questions
	13.45-14.05		The practice of orthopedic surgery in patients receiving emicizumab Dr. Tatyana Polyanskaya, MD, Moscow, Russia with the support of the JSC «Roche-Moscow»
	14.05-14.10		Questions
	14.10-14.30		Modern aspects of hemophilia A treatment Dr. Nadezhda Zozulya, MD,  Moscow, Russia with the support of the Sobi
	14.30-14.35		Questions
	14.35-14.55		Systemic mastocytosis. Unresolved problems in diagnosis and treatment Dr. Dzhariyat Shikhbabayeva, MD, Moscow, Россия with the support of the Lancet
	14.55-15.00		Questions
	15.00-15.10		General discussion Closing of the first day of the conference

April 27, 2025- Day 2

Malignant and nonmalignant hematologic disorder and allo-HSCT approaches

Plenary session

Hall 1

	Healthcare organization Chairmen Amir Ali Hamidieh, Elena Parovichnikova, Fevzi Altuntaş, Miralisher Islamov
	09.00-09.12		I - Healthcare organization: Iran Prof. Dr. Amir Ali Hamidieh, MD (Iran)
	09.12-09.15		Discussion
	09.15-09.27		R - Healthcare organization: Russia Dr. Elena Parovichnikova, MD (Russia)
	09.27-09.30		Discussion
	09.30-09.42		T - Healthcare organization: Türkiye Prof. Dr. Fevzi Altuntaş, MD (Türkiye)
	09.42-09.45		Discussion
	09.45-09.57		U - Healthcare organization: Uzbekistan Dr. Miralisher Islamov, MD (Uzbekistan)
	09.57-10.00		Discussion
	Life-threatening infections: KPE, invasive mycoses, viral infections Chairmen Burcu Çalışkan Demirkiran, Galina Klyasova, Hamid Eshaghi, Sardor Mukhammadiev
	15.15-15.27		Infections caused by carbapenemase-producing Enterobacterales in hematological patients Prof. Dr. Galina Klyasova, MD (Russia)
	15.27-15.30		Discussion
	15.30-15.42		Fungal infections in routine practice in Türkiye Dr. Burcu Çalışkan Demirkiran, MD (Türkiye)
	15.42-15.45		Discussion
	15.45-15.57		CMV infection in children undergoing hematopoietic stem cell transplantation Dr. Hamid Eshaghi, MD (Iran)
	15.57-16.00		Discussion
	16.00-16.12		Infections in allo-HSCT patients in Uzbekistan Dr. Sardor Mukhammadiev, MD (Uzbekistan)
	16.12-16.15		Discussion

Malignant and non-malignant hematological diseases

Hall 1

	Thalassemia/sickle cell anemia/AIHA Chairmen Dilora Suleymanova, Gennady Galstyan, Hadi Mottaghipisheh, Mehmet Bakırtaş, Mahmut Bakir Koyuncu
	10.00-10.12		Immune thrombocytopenia Dr. Mehmet Bakırtaş, MD (Türkiye)
	10.12-10.15		Discussion
	10.15-10.27		Tailored treatment of immune thrombotic thrombocytopenic purpura Prof., Dr. Gennady Galstyan, MD (Russia)
	10.27-10.30		Discussion
	10.30-10.42		Anemia and thalassemia in Uzbekistan Prof., Dr. Dilora Suleymanova, MD (Uzbekistan)
	10.42-10.45		Discussion
	10.45-10.57		Approach to the treatment of thalassemias in Türkiye Dr. Mahmut Bakir Koyuncu, MD (Türkiye)
	10.57-11.00		Discussion
	11.00-11.12		Modern approaches to the treatment of sickle cell anemia: from gene therapy to modern drugs Dr. Hadi Mottaghipisheh, MD (Iran)
	11.12-11.15		Discussion
	Acute leukemia/MDS Chairmen Elena Parovichnikova, Sayeh Parkhideh, Eldor Iskhakov, Rafiye Çiftçiler, Aziz Eghbali
	11.15-11.27		Clinical trials in patients with acute leukemia in Russia Dr. Elena Parovichnikova, MD (Russia)
	11.27-11.30		Discussion
	11.30-11.42		Update treatment of MDS Dr. Sayeh Parkhideh, MD (Iran)
	11.42-11.45		Discussion
	11.45-11.57		Treatment of AML with modern drugs: own experience Dr. Rafiye Çiftçiler, MD (Türkiye)
	11.57-12.00		Discussion
	12.00-12.12		Immunotherapy in pediatric acute lymphoblastic leukemia: recent advances and future perspectives Dr. Aziz Eghbali, MD (Iran)
	12.12-12.15		Discussion
	12.15-12.27		Acute leukemia and pregnancy. A rare condition with rare disease Dr. Eldor Iskhakov, MD (Uzbekistan)
	12.27-12.30		Discussion
	Multiple myeloma Chairmen Bahar Uncu Ulu, Larisa Mendeleeva, Farzaneh Ashrafi, Maxim Solovev, Gulchexra Mahamadalieva
	12.30-12.42		Monoclonal Gammopathies: More Than Just a Lab Result Dr. Farzaneh Ashrafi, MD (Iran)
	12.42-12.45		Discussion
	12.45-12.57		Primary plasma cell leukemia: diagnosis and treatment Dr. Maxim Solovev, MD (Russia)
	12.57-13.00		Discussion
	13.00-13.12		New approaches to the treatment of multiple myeloma Dr. Gulchexra Mahamadalieva, MD (Uzbekistan)
	13.12-13.15		Discussion
	13.15-13.27		Clinical trials in Türkiye Dr. Bahar Uncu Ulu, MD (Türkiye)
	13.27-13.30		Discussion
	Hodgkin’s lymphoma/NHL/CLL Chairmen Evgeny Zvonkov, Düzgün Özatlı, Nelly Gabeeva, Maryam Barkhordar, Kamoliddin Olimjonov
	13.30-13.42		Follicular lymphoma. One mask - many faces Dr. Nelly Gabeeva, MD (Russia)
	13.42-13.45		Discussion
	13.45-13.57		Approaches to the treatment of DLBC lymphoma Dr. Düzgün Özatlı, MD (Türkiye)
	13.57-14.00		Discussion
	14.00-14.12		Immune cell therapy for lymphoma Dr. Maryam Barkhordar, MD (Iran)
	14.12-14.15		Discussion
	14.15-14.27		Auto-HSCT for lymphoma patients Dr. Kamoliddin Olimjonov, MD (Uzbekistan)
	14.27-14.30		Discussion
	CML - algorithms for managing CML patients in different countries Chairmen Anna Turkina, Mehmet Sinan Dal, Ekaterina Chelysheva, Hossein Ghasemi Moghaddam
	14.30-14.42		Algorithms for managing patients with CML in Türkiye Prof. Dr. Mehmet Sinan Dal, MD (Türkiye)
	14.42-14.45		Discussion
	14.45-14.57		Treatment options for CML with an optimal response Dr. Ekaterina Chelysheva, MD (Russia)
	14.57-15.00		Discussion
	15.00-15.12		Advanced phase CML Dr. Hossein Ghasemi Moghaddam, MD (Iran)
	15.00-15.15		Discussion
	Hemophilia: today and tomorrow Chairmen Aziza Makhmudova, Cengiz Demir, MD Nadezhda Zozulya, Babak Abdolkarimi
	16.15-16.27		Hemophilia treatment in Russia Dr. Nadezhda Zozulya, MD (Russia)
	16.27-16.30		Discussion
	16.30-16.42		Hemophilia treatment Prof., Dr. Cengiz Demir, MD (Türkiye)
	16.42-16.45		Discussion
	16.45-16.57		Novel treatment approach in hemophilia Dr. Babak Abdolkarimi, MD (Iran)
	16.57-17.00		Discussion
	17.00-17.12		Approaches to the treatment of hemophilia in Uzbekistan Prof., Dr. Aziza Makhmudova, MD (Uzbekistan)
	17.12-17.15		Discussion

Approaches to transplantation

Hall 2

	Allo-HSCT in hematological malignancies Chairmen Abdurakhman Kayumov, Fevzi Altuntaş, Abbas Hajifathali, Mikhail Drokov
	10.00-10.12		Conditions and prospects for the development of HSCT in Uzbekistan Dr. Abdurakhman Kayumov, MD (Uzbekistan)
	10.12-10.15		Discussion
	10.15-10.27		The structure of adult allo-HSCT care in Russia Dr. Mikhail Drokov, MD (Russia)
	10.27-10.30		Discussion
	10.30-10.42		Hematopoietic stem cell transplantation activity in Türkiye Prof., Dr. Fevzi Altuntaş, MD (Türkiye)
	10.42-10.45		Discussion
	10.45-10.57		T-cell depletion in allogeneic hematopoietic stem cell transplant Dr. Abbas Hajifathali, MD (Iran)
	10.57-11.00		Discussion
	Aplastic anemia/ bone marrow failure syndromes and transplantation in non-malignant diseases Chairmen Amir Ali Hamidieh, Elena Mikhailova, Mehmet Bakyrtas, Vahid Falahati, Zalina Fidarova, Inna Berger
	11.00-11.12		Allogeneic hematopoietic stem cell transplantation for Inherited bone marrow failure Prof. Dr. Amir Ali Hamidieh, MD (Iran)
	11.12-11.15		Discussion
	11.15-11.27		Impaired supportive function of the stromal environment in bone marrow in aplastic anemia Dr. Inna Berger, MD (Uzbekistan)
	11.27-11.30		Discussion
	11.30-11.42		Halpoidentical hematopoetic stem cell transplantation  for severe acquired aplastic anemia Dr. Vahid Falahati, MD (Iran)
	11.42-11.45		Discussion
	11.45-11.57		Haplo-HSCT in the first line treatment for aplastic anemia with severe infections Dr. Zalina Fidarova, MD (Russia)
	11.57-12.00		Discussion
	GVHD prophylaxis/Graft failure Chairmen Maryam Behfar, Burhan Turgut, Ozoda Achilova, Natalia Popova, Mikhail Drokov
	12.15-12.27		GVHD prophylaxis approach in allo-HSCT in Türkiye Dr. Burhan Turgut, MD (Türkiye)
	12.27-12.30		Discussion
	12.30-12.42		Results of low-doses PT-Cy in the prevention of GVHD in after allo-HSCT in Uzbekistan Dr. Ozoda Achilova, MD (Uzbekistan)
	12.42-12.45		Discussion
	12.45-12.57		The impact of anti-HLA antibodies on graft failure in HSCT Dr. Maryam Behfar, MD (Iran)
	12.57-13.00		Discussion
	13.00-13.12		Graft failure: Challenges in definition. Single-center experience Dr. Natalia Popova, MD (Russia)
	13.12-13.15		Discussion
	Acute GVHD/Chronic GVHD Chairmen Mikhail Drokov, Mahmut Yeral, Leyla Jafari, Vera Vasilyeva, Saidburkhon Asilov
	13.15-13.27		Structure of acute and chronic GVHD in Uzbekistan Dr. Saidbukhon Asilov, MD (Uzbekistan)
	13.27-13.30		Discussion
	13.30-13.42		Approaches to the treatment of SR-GVHD: ruxolitinib vs ECP Prof. Dr. Mahmut Yeral, MD (Türkiye)
	13.42-13.45		Discussion
	13.45-13.57		Cryopreservation as an alternative approach for applying photopheresis products to treat GVHD among pediatric patients Dr. Leyla Jafari, MD (Iran)
	13.57-14.00		Discussion
	14.00-14.12		Therapy for steroid-refractory acute and chronic graft-versus-host disease using cryopreserved mononuclear cells subjected to extracorporeal phototherapy Dr. Vera Vasilyeva, MD (Russia)
	14.12-14.15		Discussion
	Intensive care for allo-HSCT Chairmen Gennady Galstyan, Zeinab Najafi, Ilhami Berber, Dano Julamanova
	14.15-14.27		Outcomes in critically ill allogeneic hematopoietic stem cell transplantation recipients Dr. Antonina Shchekina, MD (Russia)
	14.27-14.30		Discussion
	14.30-14.42		Thrombotic microangiopathy after HSCT Prof. Dr. Ilhami Berber, MD (Türkiye)
	14.42-14.45		Discussion
	14.45-14.57		Critical care pulmonary issues after HSCT Dr. Zeinab Najafi, MD (Iran)
	14.57-15.00		Discussion
	15.00-15.12		Intensive care in Uzbekistan Dr. Dano Julamanova, MD (Uzbekistan)
	15.12-15.15		Discussion
	Cell therapy Chairmen Abdurakhman Kayumov, Hamid Farajifard, Samet Yaman, Olga Aleshina, Farkhodjon Tashtemirov
	16.15-16.27		CAR-T therapy: evolving art of ALL treatment Dr. Olga Aleshina, MD (Russia)
	16.27-16.30		Discussion
	16.30-16.42		CAR-T cells and cell therapy in Türkiye Dr. Samet Yaman, MD (Türkiye)
	16.42-16.45		Discussion
	16.45-16.57		Adoptive T-cell therapy in CMV infection Dr. Hamid Farajifard, MD (Iran)
	16.57-17.00		Discussion
	17.00-17.12		Cell therapy needs and legislation in Uzbekistan Dr. Farkhodjon Tashtemirov, MD (Uzbekistan)
	17.12-17.15		Discussion

5 How I can get to the conference?

Important

Our conference is full free of charge. If something went wrong just start again or press Ctrl+F5

5.1 Choosing language

Please choose your language (if available) or stay on English version of site

Please click like it showed below. You will be redirected to choosing Virtual Hall

5.2 Registration

After short registration you get to the conference player.

Important

Due obtaining correct statistic about your interests at our conference. We need registration in each hall separately. Thank you for understanding.

5.3 How I can choose my language during broadcasting?

Please click like it shown below to choose your language.

April, 26 - English and Russian language will be available

April, 27 - English, Russian and Turkish (AI) language will be available

Important

We extend languages that we translate to. AI help us to provide it to you. See you next year

5.4 How I can ask my questions?

Tip

Use English for your questions. Let others know what are you talking about

Please click like it shown below to open chat and send your question. All questions will be available to speakers via link that we provide.